New treatments for headache (Q38773593)

6 September 2017

1 reference

title

New treatments for headache (English)

1 reference

6 September 2017

1 reference

Stewart J Tepper

1 reference

6 September 2017

Kasra Maasumi

1 reference

6 September 2017

Alan M Rapoport

series ordinal

1 reference

6 September 2017

publication date

1 May 2017

1 reference

6 September 2017

published in

Neurological Sciences

1 reference

6 September 2017

1 reference

6 September 2017

issue

Suppl 1

1 reference

6 September 2017

page(s)

145-156

1 reference

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Burden of migraine: international perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Menstrual Migraine and Treatment Options: Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Migraine: epidemiology, impact, and risk factors for progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Predictors of adherence to triptans: factors of sustained vs lapsed users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Calcitonin gene-related peptide (CGRP): a new target for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

CGRP and its receptors provide new insights into migraine pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Evidence for a vascular factor in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized, controlled trial of telcagepant for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Orally inhaled dihydroergotamine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Current Approaches to Neuromodulation in Primary Headaches: Focus on Vagal Nerve and Sphenopalatine Ganglion Stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Neurostimulation for Treatment of Migraine and Cluster Headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Transcranial magnetic stimulation for migraine: clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and patients’ satisfaction of transcutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly® Device for Migraine Prevention: A Review of the Available Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Non-Invasive Neuromodulation Using Time-Varying Caloric Vestibular Stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Concordant occipital and supraorbital neurostimulation therapy for hemiplegic migraine; initial experience; a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Hypothalamic involvement and activation in cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Hypothalamic deep brain stimulation for cluster headache: experience from a new multicase series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Drug-resistant cluster headache: long-term evaluation of pain control by posterior hypothalamic deep-brain stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Advances and challenges in neurostimulation for headaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-017-2910-0

Stimulation of the Posterior Hypothalamus for Treatment of Chronic Intractable Cluster Headaches: First Reported Series

21 January 2018

1 reference

12 December 2020

High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study

1 reference

12 December 2020

Low-frequency rTMS of the vertex in the prophylactic treatment of migraine

1 reference

12 December 2020

Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow-up

1 reference

12 December 2020

Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis

1 reference

12 December 2020

Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans

1 reference

12 December 2020

rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics

1 reference

12 December 2020

Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

10.1007/S10072-017-2910-0

Identifiers

DOI

1 reference

6 September 2017

1 reference